The abstract is read at the publisher; the summary is JClub's.
ASCO’s updated breast cancer follow-up guideline is built on one surveillance mammography RCT and modified Delphi consensus, with risk-based visit intensity after primary treatment.
- Why it matters: Clinicians need evidence-based, practical guidance for post-treatment surveillance, but few trials compare follow-up strategies by relapse risk in early-stage disease.
- What they did: ASCO convened an Expert Panel using a systematic review and formal consensus process, identifying one RCT for mammography and no RCTs for other follow-up approaches by relapse risk.
- The result: The guideline recommends regular history, physical exam, and mammography, allows virtual or in-person visits, and calls for closer surveillance in higher-recurrence groups while addressing biomarkers and supplemental imaging.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.